Codex Capital Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Codex Capital Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,000	Closed	-$2.63M	–	33
2025 Q2	$2.63M	Sell	5,000 -750	-13%	-$419K	1.05%	26
2025 Q1	$3.65M	Hold	5,750	–	–	1.72%	22
2024 Q4	$4.1M	Hold	5,750	–	–	1.81%	23
2024 Q3	$6.04M	Hold	5,750	–	–	2.68%	14
2024 Q2	$6.04M	Buy	+5,750	New	+$5.57M	2.77%	16

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Codex Capital Asset Management's REGN Position: Q3 2025 in Review

Codex Capital Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 5,000 shares — an estimated $2.63M sold.

Codex Capital Asset Management first reported a position in REGN in Q2 2024 and held it in 5 quarters. The position peaked at $6.04M in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Codex Capital Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Codex Capital Asset Management sold 5,000 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $2.63M.
Codex Capital Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 5 quarters.
Codex Capital Asset Management's Regeneron Pharmaceuticals position peaked at $6.04M in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Codex Capital Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.